BioSpace News Archive

Loncar Investments, LLC announced the launch of the Loncar China BioPharma Index (LCHINA), the world’s first global benchmark tracking the performance of companies leading China’s biotech revolution.

Medivir AB announced that John Öhd, Chief Medical Officer at Medivir, has decided to leave the company.

Merck announced that new research from Merck’s broad oncology clinical program – across several major tumor types, as monotherapy and in combination – will be presented at the AACR Annual Meeting 2018 in Chicago from April 14-18.

The 150 registered nurses who work at Tobey Hospital, and who are unionized with the Massachusetts Nurses Association, received welcome news last week in the form of a ratified contract and a National Labor Relations Board (NLRB) settlement that put closure to a contract fight that has been ongoing since April of 2015.

Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.

Auris Medical has gone down swinging again in attempting to develop a treatment for tinnitus after it announced its Phase III trial failed to meet endpoints.

Here’s a look at eight biopharma companies with upcoming catalysts.

Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals has secured $63.5 million in Series B financing.

Federal right-to-try legislation that would have allowed terminally ill patients access to experimental therapies without approval from the U.S. Food and Drug Administration failed to muster enough support in the U.S. House of Representatives.

PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS).